SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-056770
Filing Date
2021-11-04
Accepted
2021-11-04 16:43:41
Documents
59
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0921_protarathera.htm   iXBRL 10-Q 1060782
2 CERTIFICATION f10q0921ex31-1_protarathera.htm EX-31.1 14673
3 CERTIFICATION f10q0921ex31-2_protarathera.htm EX-31.2 14136
4 CERTIFICATION f10q0921ex32-1_protarathera.htm EX-32.1 8150
  Complete submission text file 0001213900-21-056770.txt   4464185

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tara-20210930.xsd EX-101.SCH 53912
6 XBRL CALCULATION FILE tara-20210930_cal.xml EX-101.CAL 33706
7 XBRL DEFINITION FILE tara-20210930_def.xml EX-101.DEF 215421
8 XBRL LABEL FILE tara-20210930_lab.xml EX-101.LAB 424852
9 XBRL PRESENTATION FILE tara-20210930_pre.xml EX-101.PRE 227348
10 EXTRACTED XBRL INSTANCE DOCUMENT f10q0921_protarathera_htm.xml XML 455848
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 211380576
SIC: 2836 Biological Products, (No Diagnostic Substances)